Clinical trials · New York, NY
Relapsed or Refractory Multiple Myeloma clinical trials in New York
We’re tracking 157 recruiting relapsed or refractory multiple myeloma studies with a site in or near New York — including Phase 1, Phase 1/Phase 2, Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies near New York
- NCT07518186RecruitingPhase 3
Comparing Two New Myeloma Treatments: JNJ-79635322 vs Teclistamab
This study compares two new antibody-based drugs (JNJ-79635322 and teclistamab) to see which works better for multiple myeloma that has come back or stopped responding to prior treatment. Both drugs are designed to help your immune system fight myeloma cells.
New York, New YorkAges 18 years+ - NCT07391657RecruitingPhase 3
Comparing a new CAR-T therapy to standard treatments for multiple myeloma
This trial tests a new dual-targeted cell therapy (AZD0120) against standard regimens for people with multiple myeloma that has come back or not responded to treatment. It aims to see if the new therapy works better than standard options.
New York, New YorkAges 18 years+ - NCT06943872RecruitingPhase 3
Comparing new treatments for relapsed CLL or SLL
This study tests a combination of sonrotoclax plus obinutuzumab or rituximab versus the current standard venetoclax plus rituximab for people whose CLL or SLL has come back or not responded to previous treatment. The goal is to see which approach helps keep the cancer from growing longer.
New York, New YorkAges 18 years+ - NCT07012044RecruitingPhase 1
Cedazuridine and decitabine after stem cell transplant for childhood leukemia
This trial tests if adding two chemotherapy drugs (cedazuridine and decitabine) along with a growth factor (filgrastim) can help prevent leukemia from coming back after a stem cell transplant. It is for children and young adults with high-risk acute myeloid leukemia who are in remission after transplant.
New York, New YorkAges Up to 21 years - NCT05519085RecruitingPhase 3
Test mezigdomide vs pomalidomide with standard drugs for myeloma
This Phase 3 study compares two combination treatments for multiple myeloma that has come back or not gone away (relapsed or refractory). It aims to see whether mezigdomide, along with bortezomib and dexamethasone, works better than pomalidomide with those same medicines.
New York, New YorkAges 18 years+ - NCT07059845RecruitingPhase 2
Studying mirvetuximab combos for ovarian cancer
This trial tests multiple combinations of the drug mirvetuximab soravtansine with other treatments for people with ovarian cancer. It aims to see how well these combos work and what side effects they cause.
New York, New YorkAges 18 years+ - NCT06846606RecruitingPhase 1
Study of AUTX-703 for advanced blood cancers
This trial tests an experimental drug, AUTX-703, for people with certain blood cancers (AML or MDS) that have returned or not improved after other treatments. The goal is to see if the drug is safe and helps control the disease.
New York, New YorkAges 18 years+ - NCT01804634RecruitingPhase 2
Reduced-intensity stem cell transplant for high-risk solid tumors
This trial tests a less intense type of bone marrow (stem cell) transplant from a partly matched family donor for people with high-risk solid tumors. It aims to lower treatment intensity while still using the donor’s immune system to help control the cancer.
The Bronx, New YorkAges 1–50 - NCT07218146RecruitingPhase 3
Study of ZL-1310 vs Standard Care for Relapsed Small Cell Lung Cancer
This trial tests a new drug, ZL-1310, against standard treatments for people with small cell lung cancer that has returned after initial therapy. The goal is to see if ZL-1310 works better than other options.
The Bronx, New YorkAges 18 years+ - NCT05634369RecruitingPhase 1/Phase 2
NK cell and chemotherapy trial for relapsed soft tissue sarcoma
This early-phase trial studies a type of immune cell treatment (NK cells) made from donor cells, given with chemotherapy drugs gemcitabine and docetaxel. It’s for children and young adults whose bone or soft tissue sarcoma has come back or hasn’t responded to prior treatment.
The Bronx, New YorkAges 2–40 - NCT07725380RecruitingPhase 1/Phase 2
Two drugs for relapsed sarcoma or osteosarcoma
This trial studies a new combination of two drugs, domatinostat and sirolimus, for people with sarcoma or osteosarcoma that hasn't improved after standard treatments. The goal is to see if this combination can help shrink or slow the cancer.
The Bronx, New YorkAges 12–40 - NCT07006025RecruitingPhase 1
Oral THU-decitabine for MDS that has returned or not improved
This trial tests an oral combination of two drugs (THU and decitabine) for people with myelodysplastic syndromes (MDS) whose disease has come back or not responded to at least one prior standard treatment. The goal is to see if it can help control the disease.
The Bronx, New YorkAges 18 years+ - NCT03838926RecruitingPhase 1
Testing how safe and tolerable a new drug is for blood cancers
This Phase 1 study tests how safe and tolerable trichostatin A is in adults whose blood cancers have come back or did not respond to standard treatments. It may help researchers find an effective dose while monitoring side effects closely.
Hackensack, New JerseyAges 18 years+ - NCT06630806RecruitingPhase 1
Study of an injection for relapsed or refractory myeloma
This trial tests a new injected drug for people with multiple myeloma that has returned or stopped responding to at least 3 prior treatments. The goal is to see if the drug is safe and works against the cancer.
Hackensack, New JerseyAges 18 years+ - NCT07075185RecruitingPhase 1
Gene therapy study for hard-to-treat multiple myeloma
This study tests a new gene therapy for people with multiple myeloma that has come back or stopped responding to at least 3 prior treatments. The therapy is designed to help your immune system fight the cancer cells more effectively.
Hackensack, New JerseyAges 18 years+ - NCT04561206RecruitingPhase 2
Brentuximab plus nivolumab for relapsed Hodgkin lymphoma
This Phase 2 trial studies brentuximab vedotin plus nivolumab in people whose classical Hodgkin lymphoma has come back or did not respond to treatment. It aims to shrink tumors and improve control of the disease, especially when standard options like transplant are not possible.
Hackensack, New JerseyAges 18 years+ - NCT06988488RecruitingPhase 1/Phase 2
Study of mezigdomide plus elranatamab for relapsed multiple myeloma
This trial tests a combination of two drugs, mezigdomide (a pill) and elranatamab (an injection), for people whose multiple myeloma has returned or stopped responding to prior treatments. The goal is to find the best dose and see if the combination is safe and effective.
Hackensack, New JerseyAges 18 years+ - NCT04696029RecruitingPhase 2
DFMO to prevent return of high-risk or relapsed medulloblastoma
This Phase 2 study tests DFMO (a maintenance medicine) to help stop medulloblastoma from coming back or worsening after prior treatment. It focuses on children and young people with specific high-risk tumor types or tumors that have returned or not responded well to treatment.
Hackensack, New JerseyAges Up to 21 years - NCT07681596RecruitingPhase 1/Phase 2
Study of a new drug for relapsed or refractory multiple myeloma
This trial tests an experimental drug for multiple myeloma that has come back or not responded to at least three previous treatments. It aims to see if the drug can help people whose cancer has progressed despite prior therapies including a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 antibody.
Hackensack, New JerseyAges 18 years+ - NCT07188558RecruitingPhase 3
Comparing ronde-cel to standard CAR T-cell therapy for large B-cell lymphoma
This trial tests a new treatment called ronde-cel against the usual CAR T-cell therapy for people with large B-cell lymphoma that has come back or not responded to initial treatment. The goal is to see if ronde-cel works better.
Hackensack, New JerseyAges 18 years+ - NCT07096778RecruitingPhase 2
Combination therapy for returning multiple myeloma
This trial tests a new drug called inobrodib combined with two standard treatments (pomalidomide and dexamethasone) for people whose multiple myeloma has come back or did not respond. The goal is to see if this combination can help control the cancer.
Hackensack, New JerseyAges 18 years+ - NCT05967416RecruitingPhase 1
Early-phase lymphoma trial testing a new targeted immune treatment
This Phase 1 study tests SIRPant-M, a new immune-based treatment, in adults with lymphoma that has come back or not responded to earlier care. It may help by shrinking lymphoma using either the drug alone or the drug plus a targeted radiation treatment for certain lymphoma types.
Hackensack, New JerseyAges 18 years+ - NCT04990102RecruitingPhase 1/Phase 2
Trial drug to help prevent relapse in AML
This trial tests CPX-351 to help stop acute myeloid leukemia (AML) from coming back after you’ve reached remission. It’s for people who are not able to receive a stem cell transplant and need a new way to reduce relapse risk.
Hackensack, New JerseyAges 18 years+ - NCT06541262RecruitingPhase 1/Phase 2
Silmitasertib plus chemo for relapsed solid tumors
This trial tests a new drug, silmitasertib, combined with standard chemotherapy for children and young adults with cancers that have come back or not responded to treatment. The goal is to see if this combination can shrink tumors or stop them from growing.
Hackensack, New JerseyAges Up to 30 years
Hear when a new Relapsed or Refractory Multiple Myeloma trial opens near New York, NY
We’ll email you when one opens near New York, NY — at most once a week, no account needed, unsubscribe anytime.
Relapsed or Refractory Multiple Myeloma trials in other cities
Where these studies are running near New York
Institutions with a site for the recruiting relapsed or refractory multiple myeloma studies listed above.
- Hackensack University Medical Center · 4 studies
- Memorial Sloan Kettering Cancer Center · 3 studies
- Montefiore Medical Center · 3 studies
- John Theurer Cancer Center at Hackensack University Medical Center · 2 studies
- Research Site · 2 studies
- Albert Einstein College of Medicine, Children's Hospital at Montefiore
- Astera Cancer Care
- Columbia University Irving Medical Center
What taking part in a relapsed or refractory multiple myeloma study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Looking wider? See all recruiting relapsed or refractory multiple myeloma studies in New York.
Common questions
- Are there relapsed or refractory multiple myeloma clinical trials near New York?
- Yes. We're currently tracking 157 recruiting relapsed or refractory multiple myeloma studies with a site near New York, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a relapsed or refractory multiple myeloma study near New York?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in New York to take part?
- Not necessarily. These studies have a site near New York, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a relapsed or refractory multiple myeloma trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New relapsed or refractory multiple myeloma studies open near New York regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.